Abstract

Teleflex will report its quarterly results on August 06, 2026 Pre-Market; this preview summarizes consensus forecasts for revenue, gross margin, net margin, and adjusted EPS alongside segment dynamics and the prevailing institutional stance.

Market Forecast

Consensus points to revenue of 559.60 million US dollars for the upcoming quarter, with adjusted EPS around 1.28 and EBIT near 92.68 million US dollars, implying year-over-year declines of 27.46%, 61.90%, and 52.30%, respectively. Company projections imply a pressured profitability profile; gross margin and net margin guidance were not explicitly provided in the tool data, while forecast revenue and earnings suggest tighter operating leverage.

The main business remains concentrated in North America across Vascular, Interventional, and Surgical categories. The segment with the most promising near-term recovery potential appears to be North America Vascular, contributing 236.81 million US dollars last quarter; growth indications for the segment were not present in the dataset.

Last Quarter Review

Teleflex’s last quarter delivered revenue of 548.26 million US dollars, a gross margin of 56.31%, GAAP net income attributable to the parent company of -8.15 million US dollars with a net margin of -1.49%, and adjusted EPS of 1.39; revenue and adjusted EPS decreased year over year by 21.75% and 52.23%, respectively. Quarter-on-quarter net income growth rate was 98.86%, reflecting a substantial sequential swing from the prior period’s loss level.

Business mix was led by North America Vascular at 236.81 million US dollars, North America Interventional at 204.66 million US dollars, and North America Surgical at 106.79 million US dollars. The company did not disclose segment-level year-over-year change in the provided data.

Current Quarter Outlook (with major analytical insights)

Main business trajectory

Revenue is projected at 559.60 million US dollars with a marked year-over-year decline of 27.46%, pointing to persistent headwinds against North American hospital and procedure volumes embedded in the prior guidance. The combination of a 56.31% gross margin last quarter and the forecast step-down in revenue implies that fixed-cost absorption remains a key determinant of quarterly earnings variability. While the net margin printed at -1.49% last quarter due to one-off or non-cash items, the forecast EPS profile suggests limited near-term normalization, consistent with consensus EBIT of 92.68 million US dollars and compressed operating leverage.

Most promising business vector

Within the portfolio, North America Vascular (236.81 million US dollars last quarter) stands as the largest revenue anchor and the most likely beneficiary from any stabilization in elective and semi-urgent procedure volumes. A modest sequential revenue uptick expected this quarter aligns with the estimate trajectory from 548.26 million to 559.60 million US dollars, which would ease throughput constraints for vascular access, catheters, and related disposables. If mix skews toward higher-margin disposables within Vascular, incremental gross profit dollars could outpace revenue growth even if overall margins remain under pressure, although the dataset does not provide explicit segment-level growth rates to quantify this potential.

Key stock-price swing factors this quarter

Profit conversion from the forecast revenue base is the primary swing factor because consensus embeds a 61.90% year-over-year decline in adjusted EPS and a 52.30% decline in EBIT. Any evidence of improved manufacturing yields or logistics normalization that expands gross margin from the last quarter’s 56.31% would have an outsized effect on EPS given the lower revenue denominator. The second swing factor is the cadence of order patterns from North American healthcare systems; sustained purchase order timing shifts or inventory rationalization could skew realized revenue versus estimates and influence mix-sensitive gross margins. A third element is any incremental expense tied to remediation, restructuring, or product transitions, which could keep net margin below normalized levels even if gross margin holds.

Analyst Opinions

The prevailing institutional tone is cautious, skewing toward concern about near-term margin pressure and the depth of the year-over-year earnings decline embedded in forecasts. Recent commentary from sell-side and market observers has focused on revenue headwinds in North America and lower operating leverage; the majority view emphasizes downside risk to EPS if mix and cost variances do not improve, while acknowledging potential stabilization in procedure-related demand. In this context, the majority perspective expects limited upside surprise for this print, with valuation sensitivity centered on whether gross margin can hold near the mid-50% range and whether management’s revenue cadence points to a second-half recovery trajectory.